Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 54.6%

Neg 54.6% Neu 0% Pos 0%

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $22 to $17.